Nabiximols (Sativex) for MS Spasticity, Pain, and Bladder Problems: What the Trials Show | Research

The takeaway

Clinical trials demonstrated that nabiximols (a THC/CBD spray) provided clinical benefit for spasticity, neuropathic pain, and bladder dysfunction in multiple sclerosis patients, though long-term safety data remained limited.

Read this if you have multiple sclerosis and are considering cannabinoid-based treatment for your symptoms.

Nabiximols showed efficacy for spasticity, pain, and bladder dysfunction in MS

What the researchers found

The review analyzed clinical trials of nabiximols for three MS symptoms: spasticity, neuropathic pain, and bladder dysfunction. Trials demonstrated clinical efficacy across all three symptom categories. Nabiximols was licensed in the UK in 2010 and approved in other European countries and Canada.

The European Federation of Neurological Societies recommended cannabis-based medicines as second or third-line treatment for central neuropathic pain. The review also examined psychological effects associated with cannabinoid use in large RCTs and long-term follow-up studies.

Why it matters

MS patients often struggle with spasticity, pain, and bladder problems that respond poorly to existing treatments. This review provided a comprehensive picture of nabiximols as a treatment option for all three, helping clinicians understand where it fits in the treatment hierarchy.

The numbers in context

Nabiximols is a 1:1 THC/CBD extract. Licensed in UK in 2010. Recommended as 2nd or 3rd-line treatment for central neuropathic pain by the European Federation of Neurological Societies.

How the study worked

Narrative review of clinical trials and regulatory decisions regarding nabiximols (Sativex) for MS symptoms. Focused on randomized controlled trials for spasticity, pain, and bladder dysfunction, plus long-term follow-up and safety data.

What this study cannot tell us

Long-term safety data were still sparse at the time of publication. MS is a progressive disease, so questions remained about whether nabiximols maintains efficacy as the disease advances. The natural history of MS makes long-term efficacy evaluation challenging.

How to read the evidence

Review of multiple RCTs with regulatory approval decisions; moderate evidence base.

When this study was published

Published in 2012. Additional long-term safety and efficacy data have since become available.

The bigger picture

Nabiximols represents one of the most thoroughly studied and widely approved cannabinoid medicines. Its journey from clinical trials to regulatory approval provides a model for how other cannabinoid-based treatments might reach the clinic.

Questions still open

Does nabiximols maintain efficacy over years of use in progressive MS? What is the long-term safety profile? Are there subgroups of MS patients who respond particularly well or poorly?

Common questions

What MS symptoms can nabiximols treat?

Clinical trials showed benefits for three major MS symptoms: spasticity (muscle stiffness and spasms), neuropathic pain (nerve-related pain), and bladder dysfunction. It is positioned as a second or third-line treatment when first-line options have not provided adequate relief.

Is nabiximols the same as medical marijuana?

Not exactly. Nabiximols (brand name Sativex) is a standardized pharmaceutical extract from cannabis plants containing a precise 1:1 ratio of THC and CBD. Unlike medical marijuana, it delivers a consistent dose through a mouth spray and has gone through formal clinical trials and regulatory approval processes.

Read the original research

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.

Expert opinion on biological therapy, 12(11), 1517-31

View on PubMed ↗Publisher’s paper ↗

Citation

Podda, Giulio; Constantinescu, Cris S. (2012). Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.. Expert opinion on biological therapy, 12(11), 1517-31. https://doi.org/10.1517/14712598.2012.721765